Psilocybin & PTSD
60% response rate in veterans at 3 weeks
In the first psilocybin pilot study exclusively in US military veterans, 60% showed clinical response and 53% achieved remission at 3 weeks. At 12 weeks, 47% maintained that response despite severe treatment-resistant depression and PTSD comorbidity.
Ellis et al., Journal of Affective Disorders, 2025
0 RCTs
of psilocybin specifically for PTSD existed as of late 2024, despite 134 registered psilocybin trials across 54 indications (Dodds 2025; Norring 2024)
25 mg COMP360
the first psilocybin PTSD safety trial dose, tested by McGowan, Yehuda, and Goodwin across UK and US sites (published 2025)
TrkB binding
Moliner 2023 (Nature Neuroscience): psilocybin directly binds the BDNF receptor, producing neuroplasticity effects independently of the psychedelic experience
Ellis et al., Journal of Affective Disorders, 2025
View as image ↗The first clinical trial to test psilocybin's safety specifically in PTSD patients published its results in 2025. The same year brought the first open-label pilot study exclusively in US military veterans. Both found psilocybin safe and tolerable, with meaningful efficacy signals in a population where standard treatments consistently fall short.
That convergence points to a specific argument the research is now building: veterans with PTSD need their own research program, not results borrowed from general depression and anxiety trials. Military PTSD has features — TBI comorbidity, moral injury, help-seeking barriers shaped by military culture — that general-population studies do not account for. And the neurobiology of PTSD suggests that psilocybin's specific mechanisms may be unusually well-suited to it.
This article covers what the 2025 data shows, why the neurobiological case for psilocybin in PTSD is strong, and what the active trial landscape looks like for veterans specifically. The full clinical evidence base for psilocybin in PTSD across all populations is covered in the guide to psilocybin for PTSD: what the clinical trials show.
Key Takeaways
- The 2025 McGowan COMP360 trial was the first published clinical study testing psilocybin safety and tolerability in PTSD patients specifically; it found psilocybin safe and tolerable at 25 mg across UK and US sites
- The Ellis 2025 pilot (n=15 US military veterans with severe TRD) found 60% clinical response and 53% remission at Week 3; at Week 12, 47% maintained response. Comorbid PTSD did not significantly worsen outcomes
- As of late 2024, zero published randomized controlled trials of psilocybin for PTSD existed, despite 134 registered psilocybin trials across 54 indications (Dodds 2025; Norring 2024)
- Psilocybin facilitates fear extinction in preclinical models in a dose-dependent way via 5-HT2A receptor activation, directly targeting PTSD's core neurobiological impairment (Catlow 2013; fear extinction 2024)
- Moliner 2023 (Nature Neuroscience) found psilocybin directly binds to TrkB, the BDNF receptor, producing neuroplasticity effects that may repair PTSD's structural brain damage independently of the psychedelic experience
- NCT05554094 (Ohio State and Baylor University) is the first published protocol for a dedicated veteran PTSD psilocybin trial, using dose escalation (15 mg + 25 mg) combined with psychotherapy
Why Standard PTSD Treatments Leave a Third of Veterans Without Relief
Standard first-line treatments for PTSD — prolonged exposure therapy, cognitive processing therapy, and SSRIs — have solid evidence bases and help a substantial proportion of patients. They also fail a substantial proportion. Across clinical trial data, somewhere between a third and half of patients do not show adequate response to first-line treatments. For the large segment of the veteran PTSD population that falls into that non-response category, the options narrow to off-label medications, treatment augmentation strategies, and watchful waiting.
The veteran population has specific features that compound that failure rate. Traumatic brain injury is common in combat veterans and affects the prefrontal cortex and hippocampus, which are central to PTSD symptom maintenance and therapeutic change. Damage in those regions may reduce responsiveness to therapies that rely on prefrontal engagement — including the exposure-based therapies that are PTSD's gold standard.
Moral injury is a second complicating factor. The experience of perpetrating, witnessing, or failing to prevent acts that violate one's moral beliefs produces a form of psychological suffering that overlaps with PTSD in its surface presentation but differs in its core mechanism. Fear-based therapies are designed for fear-based disorders. Moral injury is not primarily a fear disorder — it is a meaning-making failure, a rupture in the story the person tells about who they are and what they have done. Exposure-based protocols were not designed to address it.
Help-seeking barriers in military culture create a third layer. Veterans who do not present for treatment cannot receive it, regardless of treatment efficacy. Stigma around mental health in military contexts reduces the population that engages with formal treatment systems.
The Ellis 2025 pilot enrolled US military veterans with severe treatment-resistant depression and found that 33.2% of the cohort also met criteria for comorbid PTSD.[2] That comorbidity rate reflects a clinical reality: in veteran populations, TRD and PTSD frequently travel together. Treatment programs that target one without the other are operating with an incomplete picture of the patient.
The COMP360 PTSD Safety Trial — The First Published Study of Its Kind
Before 2025, no published clinical trial had specifically tested psilocybin's safety and tolerability in patients whose primary diagnosis was PTSD. Efficacy signals had come from depression, cancer, end-of-life, and general anxiety trials — conditions where PTSD was a comorbidity or an exclusion criterion, not the target.
McGowan and colleagues published a multicenter, non-randomized open-label trial of 25 mg COMP360 psilocybin in PTSD patients in 2025.[1] The trial ran from June 2022 through February 2024 at sites in the United Kingdom and the United States. The authorship reflected a deliberate combination of expertise: McGowan and Rucker as the clinical trial leads, Yehuda as a leading PTSD researcher, and Goodwin who had led the COMP360 depression development program. The design united PTSD expertise with psilocybin development experience in a way that earlier safety work had not.
The trial found psilocybin safe and tolerable in PTSD patients. This is not a trivial finding. PTSD patients respond differently to altered states than people without trauma histories. Dissociation during sessions, triggering of traumatic memories, difficulty containing intense emotional experiences — these are legitimate safety concerns specific to this population. The COMP360 data established that with appropriate clinical management, these concerns did not translate into serious adverse events at a rate that would preclude further research.[1]
The COMP360 trial recruited from general PTSD populations, not specifically veterans. But it represents the first published safety foundation on which military-focused psilocybin PTSD trials can build. Before a dedicated veteran PTSD RCT can proceed to Phase 2 or Phase 3, the basic safety profile in PTSD patients needs to be established. The McGowan study was that first step.
The First Exclusively Veteran Data — What Ellis 2025 Found
The first psilocybin study exclusively in US military veterans was published in the Journal of Affective Disorders in 2025. Fifteen veterans with severe treatment-resistant depression received a single dose of psilocybin in an open-label pilot design — described by the authors as "first-in-kind" for exclusively military veteran populations.[2]
The response rates were substantial. At Week 3, 60% showed clinical response and 53% met remission criteria. At Week 12, 47% maintained response and 40% maintained remission. In a population characterized by severe treatment resistance — meaning prior antidepressant treatments had already failed — those rates would be notable in any drug trial.[2]
The PTSD comorbidity finding is clinically important in its own right. In standard antidepressant trials, comorbid PTSD typically predicts worse outcomes — PTSD's presence makes depression harder to treat. In the Ellis study, comorbid PTSD did not significantly worsen psilocybin response. If this finding holds in larger and controlled trials, it would suggest that psilocybin is less sensitive to PTSD comorbidity than conventional antidepressants, which would be directly relevant to the veteran population where both conditions frequently co-occur.
The study was small, open-label, and had no control condition. The response rates cannot be compared against a placebo arm. These are meaningful limitations for drawing conclusions about efficacy. What the Ellis study establishes is that psilocybin is feasible and tolerable in this population, that the comorbidity picture common in veterans does not preclude response, and that a controlled veteran PTSD trial is warranted. That is what a proof-of-concept pilot is supposed to establish.
The Gap That Drives the Push — Zero Psilocybin PTSD RCTs
Understanding why the push for military-focused psilocybin PTSD research has accelerated requires understanding the gap between interest and evidence.
A 2025 comprehensive systematic review by Dodds and colleagues examined all novel psychedelic interventions for PTSD — psilocybin, MDMA, ketamine, and others.[3] Their finding: as of late 2024, there were no published randomized controlled trials of psilocybin specifically for PTSD in any population. Not veterans specifically. Not anyone. Zero.
This is not because psilocybin research is absent at scale. A 2024 landscape analysis by Norring and colleagues counted 134 registered psilocybin trials across 54 potential indications as of their analysis date, with zero marketing approvals.[4] The research infrastructure is massive. PTSD-specific trial data simply has not materialized yet, because trials in depression, cancer, and addiction have proceeded faster and with more established evidence bases.
A 2025 systematic review of four psychedelic-assisted therapies — MDMA, psilocybin, ketamine, and LSD — for depression and PTSD found that MDMA carried the strongest PTSD-specific evidence signal while psilocybin carried the strongest depression evidence signal.[5] MDMA was positioned as the frontrunner for an approved psychedelic PTSD treatment. When the FDA rejected the Lykos Therapeutics application for MDMA-assisted therapy in 2024, citing methodological concerns with the pivotal trials, it removed the field's best candidate for PTSD-specific approval and significantly increased the urgency for psilocybin PTSD research as an alternative path.
The situation as of 2025: compelling safety data (McGowan), promising veteran-specific pilot data (Ellis), a clear mechanistic rationale, and zero completed RCTs. That is the gap. The "push" in the headline reflects the fact that veterans who need this treatment are waiting for research that is still in its first generation.
Why the Brain Biology Points Toward Psilocybin for PTSD
The mechanistic argument for psilocybin in PTSD runs through three parallel evidence lines: fear extinction, neuroplasticity, and network reorganization.
PTSD is, at the neurobiological level, a disorder of impaired fear extinction. The normal process by which the brain updates fear associations — learning that a previously dangerous stimulus is no longer threatening — breaks down. Traumatic memories resist extinction, producing intrusive re-experiencing and hypervigilance that persist long after the original threat has passed.
A 2024 mechanistic review mapped the pathways by which psilocybin may address this: 5-HT2A receptor agonism drives disruption of the default mode network's rigid activity patterns; fear extinction circuits are directly enhanced; memory reconsolidation is facilitated; downstream neuroplasticity is stimulated.[6]
The fear extinction evidence runs from preclinical to recent mechanistic work. Catlow and colleagues demonstrated in 2013 that psilocybin promotes hippocampal neurogenesis and accelerates fear extinction in mice — the foundational preclinical finding that first linked psilocybin to trauma-relevant mechanisms.[7] A 2024 study confirmed that psilocybin facilitates fear extinction in a dose-dependent and context-dependent way, primarily through 5-HT2A receptor activation.[8] The dose-dependence is clinically relevant: the doses used in therapeutic settings are the doses that produce robust fear extinction enhancement in preclinical models.
The neuroplasticity evidence is equally strong. PTSD involves structural brain changes: reduced hippocampal volume, decreased prefrontal activity, altered amygdala reactivity. Standard antidepressants produce symptomatic improvement in some patients without consistently reversing these structural changes.
Ly and colleagues' 2018 Cell Reports study established that psychedelics promote dendritic spine growth and synaptogenesis in cortical neurons, producing structural changes comparable to rapid-acting antidepressants at the cellular level.[9] A 2021 study found that a single psilocybin dose increased synaptic density by approximately 10% in pig frontal cortex within 24 hours, with effects lasting at least one month.[10]
The most mechanistically significant recent finding came from Moliner and colleagues, published in Nature Neuroscience in 2023. Psilocybin and other psychedelics directly bind to TrkB, the primary receptor for brain-derived neurotrophic factor — the brain's main growth and repair signal.[11] This direct TrkB binding produces neuroplasticity effects independently of 5-HT2A, meaning structural repair may be possible through pharmacological mechanisms that do not require the psychedelic experience itself to occur.
For veteran populations, where managing the experiential intensity of psilocybin sessions presents real clinical and logistical challenges, the possibility of neuroplasticity through sub-perceptual or lower-dose protocols opens a different treatment design space than the current high-dose paradigm.
For more on the fear extinction mechanism specifically, the companion piece on fear extinction and psilocybin covers how psychedelics may reprocess trauma memories at the circuit level.
The Active Trial Landscape — What Veteran-Focused Research Looks Like Now
The most concrete expression of the push for veteran-specific psilocybin research is NCT05554094. Davis and colleagues published its protocol in 2023: an open-label proof-of-concept trial at Ohio State University and Baylor University, enrolling 15 US military veterans with severe treatment-resistant PTSD who have not responded to at least two first-line treatments.[12]
The protocol calls for two psilocybin sessions: a 15 mg first session followed by a 25 mg second session, both combined with psychotherapy. The dose escalation structure reflects lessons from cancer and depression trials — the first session allows the patient and clinical team to calibrate response before proceeding to a full therapeutic dose. Publishing the protocol publicly before trial completion creates a reference design for other researchers building subsequent veteran PTSD protocols.
The broader landscape reflects a 2024 meta-analysis confirming that psychedelics show meaningful effect sizes across multiple mental health conditions, providing the broader efficacy signal that supports expanding into PTSD-specific trials.[13] VA research infrastructure is now engaged: nine VA facilities are involved in psychedelic research implementation, organized through an Integrated Project Team chartered in 2024.
The gap between what the science supports and what veterans can access remains wide. The McGowan safety data, the Ellis pilot response rates, the preclinical fear extinction and neuroplasticity mechanisms, and the NCT05554094 protocol together represent the first generation of a research program that veterans and researchers are building simultaneously. The randomized controlled trial data that would move this from promising to proven has not been published yet.
For the full picture of where psilocybin PTSD trials stand across all populations, the companion piece on psilocybin PTSD clinical trials: preliminary data covers what has been published and what is active. The companion piece on can psilocybin help first responders with PTSD? covers how the military veteran data connects to adjacent high-risk occupational populations. And for context on how psilocybin compares to MDMA as a PTSD treatment approach, psilocybin vs. MDMA for PTSD covers the mechanistic differences between the two.
The Bottom Line
The first published psilocybin PTSD safety study (McGowan 2025, COMP360) and the first veteran-specific pilot (Ellis 2025, 60% response at 3 weeks) both appeared in 2025, representing the first generation of dedicated research in this area. As of late 2024, zero randomized controlled trials of psilocybin for PTSD had been published, despite 134 registered trials. The neurobiological case rests on fear extinction facilitation, structural neuroplasticity from Ly 2018 and Moliner 2023's TrkB finding, and network reorganization. NCT05554094 (Ohio State and Baylor) is the first published protocol for a veteran-specific psilocybin PTSD trial.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2RTHM-00923·Ellis, Sara et al. (2025). “Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study..” Journal of affective disorders.Study breakdown →PubMed →↩
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.
- 8. Source details for this reference are not yet available.
- 9RTHM-00983·Ly, Calvin et al. (2018). “Psychedelics Promote Structural and Functional Neural Plasticity..” Cell reports.Study breakdown →PubMed →↩
- 10. Source details for this reference are not yet available.
- 11. Source details for this reference are not yet available.
- 12. Source details for this reference are not yet available.
- 13. Source details for this reference are not yet available.